Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06614504 · ClinicalTrials.gov registry record · Phase 2
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
A Phase 2 study of Tobacco Use Disorder, sponsored by University of Vermont.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 2
- Study locations
NCT06614504 is a Phase 2 study of Tobacco Use Disorder that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 308 participants, above the 235-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (31% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06614504, a Phase 2 study of Tobacco Use Disorder, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potenti
Conditions Studied
Interventions
- OTHER Varying the nicotine content of cigarettes
- OTHER Varying the nicotine content of e-cigarettes
Study Locations (2)
Rhode Island
- Brown University - Providence
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06614504
The ClinicalTrials.gov registry entry for NCT06614504 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 235-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (31% higher). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Varying the nicotine content of cigarettes is the first listed.
NCT06614504 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Rhode Island, Vermont.
Frequently Asked Questions
What is clinical trial NCT06614504 about?
NCT06614504 is a clinical study titled "Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes". Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, complete...
What is the current status of trial NCT06614504?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2024-11-01. Estimated completion is 2028-09-30.
What conditions does trial NCT06614504 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT06614504?
The interventions under investigation include: Varying the nicotine content of cigarettes (OTHER), Varying the nicotine content of e-cigarettes (OTHER).
Who is sponsoring clinical trial NCT06614504?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06614504 being conducted?
This trial has 2 study locations across Rhode Island, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
-
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.